Glidepath Health launched with backing from AlleyCorp and A-Squared Ventures and an exclusive license to Memorial Sloan Kettering's ImmunoChain technology. The company is betting that the operational logistics of cell and gene therapy, not the biology, now limit who gets treated.
Euclyd raised over EUR200 million to build AI inference silicon without a GPU. Samsung co-led the round, ASML's former chief executive chairs the board, and the first commercial systems are scheduled for 2028. The thesis is credible. The execution risk is real.
EnduroSat closed a $205 million round co-led by Riot Ventures and Atreides Management. The money buys a US manufacturing plant, a hub on a former Bulgarian airbase, and a wager that satellites can be built like drones.
REGENT Craft raised $240M and flew the first human-crewed all-electric Seaglider. With zero commercial deliveries against a $10B order book, the investment case rests on certification and the manufacturing ramp at its Rhode Island factory.
Battery deployment keeps setting records, but storage financing has split in two. Contracted platforms like Actis-backed Nozomi lock in 15-20 year revenue; Equinor's East Point takes merchant risk in Texas. The chemistry is commoditising. The contract is the asset.
A Dallas biotech left stealth with $15.5 million and a first-in-class candidate designed to lower blood alcohol in the emergency department. The preclinical number is striking. The human question is open.
DeepSeek released V4.1-Flash with 552B parameters, cut API output prices by roughly 70%, and is now preparing an in-house inference chip and a potential Shanghai STAR Market listing.
Antwerp fabless spin-out Tusk IC closed a €15M Series A, led by Matterwave Ventures, FORWARD.one and the Flanders Future Tech Fund, to take its standard-CMOS Ka-band beamformer chips from prototype into volume production — a cheaper route to the flat-panel antennas satellite broadband depends on.